Envisioning Glucose Transporters (GLUTs and SGLTs) as Novel Intervention against Cancer: Drug Discovery Perspective and Targeting Approach
Authors:
- 1 February 2025
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 26 (2) , 109-131
Abstract
Metabolic reprogramming and altered cellular energetics have been recently established as an important cancer hallmark. The modulation of glucose metabolism is one of the important characteristic features of metabolic reprogramming in cancer. It contributes to oncogenic progression by supporting the increased biosynthetic and bio-energetic demands of tumor cells. This oncogenic transformation consequently results in elevated expression of glucose transporters in these cells. Moreover, various cancers exhibit abnormal transporter expression patterns compared to normal tissues. Recent investigations have underlined the significance of glucose transporters in regulating cancer cell survival, proliferation, and metastasis. Abnormal regulation of these transporters, which exhibit varying affinities for hexoses, could enable cancer cells to efficiently manage their energy supply, offering a crucial edge for proliferation. Exploiting the upregulated expression of glucose transporters, GLUTs, and Sodium Linked Glucose Transporters (SGLTs), could serve as a novel therapeutic intervention for anti-cancer drug discovery as well as provide a unique targeting approach for drug delivery to specific tumor tissues. This review aims to discussthe previous and emerging research on the expression of various types of glucose transporters in tumor tissues, the role of glucose transport inhibitors as a cancer therapy intervention as well as emerging GLUT/SGLT-mediated drug delivery strategies that can be therapeutically employed to target various cancers.Keywords
This publication has 242 references indexed in Scilit:
- SGLT1 is required for the survival of triple‐negative breast cancer cells via potentiation of EGFR activityMolecular Oncology, 2019
- Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptakeInternational Journal of Cancer, 2017
- Cellular metabolism of tumor‐associated macrophages – functional impact and consequencesFEBS Letters, 2017
- Sodium/myo-inositol cotransporter 1 and myo-inositol are essential for osteogenesis and bone formationJournal of Bone and Mineral Research, 2010
- The protein family of glucose transport facilitators: It's not only about glucose after allIUBMB Life, 2010
- Inhibition of cell proliferation in human breast tumor cells by antisense oligonucleotides against facilitative glucose transporter 5Journal of Cellular Biochemistry, 2004
- Expression and localization of GLUT1 and GLUT12 in prostate carcinomaCancer, 2003
- Expression of facilitative glucose transport proteins during development of squamous cell carcinomas of the head and neckInternational Journal of Cancer, 1999
- Overexpression of glut1 and glut3 in stage I nonsmall cell lung carcinoma is Associated with poor survivalCancer, 1997
- Overexpression of glut-1 glucose transporter in human breast cancer an immunohistochemical studyCancer, 1993